Tumor Size Matters—Understanding Concomitant Tumor Immunity in the Context of Hypofractionated Radiotherapy with Immunotherapy

Tumor Size Matters—Understanding Concomitant Tumor Immunity in the Context of Hypofractionated Radiotherapy with Immunotherapy

The purpose of this study was to determine the dynamic contributions of different immune cell subsets to primary and abscopal tumor regression after hypofractionated radiation therapy (hRT) and the impact of anti-PD-1 therapy. A bilateral syngeneic FSA1 fibrosarcoma model was used in immunocompetent...

Full description

Bibliographic Details
Main Authors: Jean Philippe Nesseler, Mi-Heon Lee, Christine Nguyen, Anusha Kalbasi, James W. Sayre, Tahmineh Romero, Philippe Nickers, William H. McBride, Dörthe Schaue
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
fibrosarcoma
tumor size
radiation therapy
programmed cell death protein 1
Online Access:https://www.mdpi.com/2072-6694/12/3/714

Similar Items

Similar Items